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http://dx.doi.org/10.1016/j.ccell.2016.08.017SUMMARYIsocitrate dehydrogenase 1 mutations drive human gliomagenesis, probably through neomorphic enzyme ac-
tivity that produces D-2-hydroxyglutarate. To model this disease, we conditionally expressed Idh1R132H in the
subventricular zone (SVZ) of the adult mouse brain. The mice developed hydrocephalus and grossly dilated
lateral ventricles, with accumulation of 2-hydroxyglutarate and reduced a-ketoglutarate. Stem and transit
amplifying/progenitor cell populations were expanded, and proliferation increased. Cells expressing SVZ
markers infiltrated surrounding brain regions. SVZ cells also gave rise to proliferative subventricular nodules.
DNA methylation was globally increased, while hydroxymethylation was decreased. Mutant SVZ cells overex-
pressedWnt,cell-cycleandstemcell genes,andsharedanexpressionsignaturewithhumangliomas. Idh1R132H
mutation in the major adult neurogenic stem cell niche causes a phenotype resembling gliomagenesis.INTRODUCTION
Gliomas are the most frequent primary brain tumor. They have
diverse morphology, genetic status, and response to therapy.Significance
Few curative treatments are available for human brain tum
malignancies, probably causing tumorigenesis through D-2-
mechanisms remain unclear. We found that adult mice express
features of gliomagenesis, including increased numbers of
included cellular infiltration into surrounding brain regions, rem
the Idh1R132H SVZ closely overlaps those of human gliomas. L
motion of a neural stem cell phenotype,Wnt pathway activation
Idh1R132H mouse provides a system for assessing brain tumor
578 Cancer Cell 30, 578–594, October 10, 2016 ª 2016 The Author(s
This is an open access article under the CC BY license (http://creativeGrade I gliomas are characterized by slow growth. Grade II/III
gliomas are invasive and progress to higher-grade lesions with
poor prognosis. Glioblastoma (grade IV, GBM), the most com-
mon and most aggressive glioma, may develop rapidly withoutors. IDH1R132H is a driver mutation in gliomas and other
hydroxyglutarate accumulation, although the downstream
ing Idh1R132H in the brain subventricular zone (SVZ) develop
neural stem cells and their progeny. Other abnormalities
iniscent of tumor invasion. The gene expression profile of
ikely, non-exclusive tumorigenic mechanisms included pro-
, maintenance of telomeres, and DNA hypermethylation. Our
therapies in vivo.
). Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
evidence of a less malignant precursor lesion (primary), or less
often by progression of a lower grade tumor (secondary). Most
grade II/III gliomas and secondary GBMs carry mutations in
one of isocitrate dehydrogenase genes IDH1 or IDH2 (Losman
and Kaelin, 2013). IDH1 or IDH2 mutations are early events in
gliomagenesis, are negatively associated with PTEN mutation
and EGFR amplification, and in the astrocytoma sub-type of
glioma, are positively associated with TP53 mutation (Gupta
et al., 2011; Reitman and Yan, 2010). IDH driver mutations are
also found in acute myeloid leukemia (AML) (Mardis et al.,
2009), cholangiocarcinoma (Borger et al., 2012), enchondroma
(Amary et al., 2011; Pansuriya et al., 2011), chondrosarcoma
(Amary et al., 2011), and occasionally, other tumors. How IDH
mutations contribute to tumorigenesis is largely unknown.
IDH1 and IDH2 convert isocitrate to a-ketoglutarate (aKG) by
oxidative decarboxylation, also generating NADPH. These en-
zymes share sequence and functional homology. IDH1 is found
in the cytoplasm and peroxisome where it acts in lipid and
glucose metabolism and protects against reactive oxygen spe-
cies (ROS). IDH2 localizes to themitochondria, where it regulates
the tricarboxylic acid (TCA) cycle (Reitman and Yan, 2010).
In gliomas, IDH1R132H is the most common mutation (Parsons
et al., 2008). Initial in vitro studies found that mutant IDH1 had
decreased affinity for isocitrate (Zhao et al., 2009) and led to
reduced aKG and NADPH levels (Yan et al., 2009; Zhao et al.,
2009). Thus, IDH1 mutations were initially thought to cause tu-
mors by loss of function. Subsequent studies showed mutant
IDH1 gained an enzymatic function that converts aKG to D-2-hy-
droxyglutarate (D2HG) (Dang et al., 2009). D2HGwas postulated
to be an ‘‘oncometabolite’’ based on reports of brain tumors in
patients with congenital L2HGDH (L-2-hydroxyglutarate dehy-
drogenase) deficiency, in whom L2HG accumulates because it
cannot be metabolized to aKG (Aghili et al., 2009; Moroni
et al., 2004; Patay et al., 2012, 2015). Further in vitro data showed
that provision of D2HG in IDH1/2-wild-type hematopoietic cells
had similar leukemogenic activity to IDH1 mutations (Losman
and Kaelin, 2013). The tumorigenic effects of D2HG may derive
from modulating aKG-dependent enzymes such as JmjC
domain histone demethylases (JHDMs), TET 5-methylcytosine
hydroxylases that convert 50-methylcytosine (5mC) to 50-hydrox-
ymethylcytosine (5hmC) (Xu et al., 2011), and prolyl hydroxylases
(PHDs) that have targets such as HIF1a and collagen (Borger
et al., 2012; Chowdhury et al., 2011; Duncan et al., 2012;
Figueroa et al., 2010; Hirata et al., 2015; Lu et al., 2012; Sasaki
et al., 2012b; Tarhonskaya et al., 2014; Xu et al., 2011). Evidence
for these possibilities varies: for example, HIF pathway changes
reported in IDH1mutants vary from activation through no change
to inactivation.
Several mice carrying pathogenic Idh1 or Idh2mutations have
been analyzed. Sasaki et al. (2012b) conditionally expressed
Idh1R132H in hematopoietic lineages, leading to raised progenitor
cell numbers and extra-medullary hematopoiesis. Mutant cells
showed increased histone and DNA methylation, consistent
with findings in human AML (Figueroa et al., 2010). Knockin of
Idh1R132H in brain progenitors from E10.5 using nestin-Cre
caused neonatal death due to brain hemorrhages and high levels
of apoptosis (Sasaki et al., 2012a). No stem cell abnormalities
were observed in these mice, but HIF1a was stabilized and
collagen maturation was aberrant. Histone lysine methylationwas unchanged, but in very early embryos, 5hmC levels were
greatly reduced. In a parallel experiment using GFAP-Cre, which
acts from E14.5 in neural stem cells (NSCs), 60% of mice
suffered brain hemorrhages, and few survived to adulthood.
Akbay et al. (2014) ubiquitously expressed mutant Idh2 (R140Q
or R172K) in 5-week-old mice, resulting in cardiomyopathy and
white matter abnormalities throughout the CNS. None of these
Idh-mutant mice developed phenotypes clearly related to brain
tumorigenesis.
There is evidence that many human gliomas arise from the
subventricular zone (SVZ, also known as the V-SVZ), the largest
NSC niche in the adult mammalian brain (Ihrie and Alvarez-
Buylla, 2011). In the canonical model of normal SVZ lineage pro-
gression, quiescent NSCs become activated and generate
rapidly dividing transit amplifying progenitor (TAP) cells. These,
in turn give rise to lineage committed neuroblasts or glioblasts
that differentiate and in mice migrate to the olfactory bulb.
How the stem cell niche generates brain tumors is not well un-
derstood, but evidence supports a link between SVZ NSCs
and gliomas. First, Wnt, EGF, SHH, and PDGF signaling are
necessary for SVZ stem cell self-renewal and proliferation, and
are also implicated in tumorigenesis (Jackson and Alvarez-
Buylla, 2008). Second, nestin and other SVZ stem cell markers
are highly expressed in GBMs (Haskins et al., 2013; Singh
et al., 2004). Finally, mutations or aberrant expression of genes
such as Kras, Pdgfb, Trp53, Ptch1, and Pten in the SVZ of
mice can elicit tumors (Fomchenko and Holland, 2006; Holland,
2001; Huse and Holland, 2009). Multiple genetic perturbations
are often necessary for progression from hyperproliferation to
full-blown SVZ tumors.
We wondered whether the existing Idh1R132H mice had not
developed features of brain tumors because the mutant protein
was deleterious in embryos or young animals. Consistent with
this notion, we noted that germline IDH mutations had not
been reported in patients with gliomas or AML, and that the
few patients with constitutional IDH mutations were mosaics
(Amary et al., 2011). We therefore investigated the consequence
of expressing Idh1R132H specifically in adult NSCs and progen-
itor cells in mice.
RESULTS
Knockin of Idh1fl(R132H)/+ in the Adult Mouse SVZ Stem
Cell Niche
To generate Idh1fl(R132H)/+ knockin mice, we designed a replace-
ment targeting construct to conditionally express the Idh1R132H
mutation under the control of the endogenous promoter (Fig-
ure 1A) following recombination at loxP sites. Initially we targeted
the mutation specifically to brain stem/progenitor cells by
crossing Idh1fl(R132H)/+ animals with nestin-Cre mice, thus
inducing efficient recombination throughout the CNS from
E10.5 (Tronche et al., 1999). As expected, these Idh1-KI mice
died perinatally and exhibited brain hemorrhages (Sasaki et al.,
2012a) (Figure S1A). We then crossed Idh1fl(R132H)/+ animals
with mice carrying a tamoxifen-inducible nestin-CreER(T2), which
in adult mice targets Cre to the SVZ and the other major neuro-
genic niche, the subgranular zone (SGZ) of the hippocampal
dentate gyrus (Lagace et al., 2007). We confirmed this using
Rosa26-YFP reporter mice (Figure 1B). Tamoxifen was given toCancer Cell 30, 578–594, October 10, 2016 579
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the Nes-CreER(T2); Idh1fl(R132H)/+ mice at 5–6 weeks of age for 5
consecutive days (Tam-Idh1-KI mice) (Figure 1C). We showed
that R132H knockin had occurred by sequencing DNA and
mRNA from forebrain and microdissected SVZ (Figure 1D).
Throughout the studies described below, we compared Tam-
Idh1-KI mice with Idh1-wild-type controls (see Experimental
Procedures), all of which were given the same regimen of
tamoxifen. The Tam-Idh1-KI animals began to suffer morbidity
and mortality 4–6 weeks after tamoxifen administration, neces-
sitating culling of about one-third of them at this stage and all
by 12 months of age (Figure 1E). Weight loss was usually the
first apparent abnormality (Figure 1F), often accompanied by
hunched posture and hyperactivity (Figure 1G). Control mice
showed none of these problems. Postmortem analysis was
performed on 45 Tam-Idh1-KI mice aged 2–12 months. The
brains of 19 (42%) animals were grossly uniformly enlarged
and less firm (Figure 1H); controls did not show these changes.
Craniofacial morphology and skull size appeared normal in
Tam-Idh1-KIs, and no brain hemorrhages or gross abnormal-
ities outside the brain were found. Closer visual examination,
confirmed by magnetic resonance images, showed enlarged
lateral ventricles (LVs), and possibly enlarged third ventricles,
in all Tam-Idh1-KI animals (Figures 1I, S1B, and S1C). These
appearances were suggestive of obstructive (non-communi-
cating) hydrocephalus.
Idh1R132H Expands the SVZ
Histological analysis of H&E-stained sections of brain in the
sagittal and coronal planes demonstrated lateral ventricular dila-
tion in all Tam-Idh1-KI animals, including both the youngest mice
examined (2 months old) and mice with no abnormal physical
signs or gross brain enlargement (details not shown). There
was also enlargement of the SVZ, with irregular lateral borders,
and an expansion of the rostral migratory stream (RMS) (Fig-
ure 2A). Furthermore, Ki67 immunohistochemistry (IHC) showed
increased numbers of proliferative cells in the SVZ of Tam-Idh1-
KI mice (Figure 2B), and these cells spread into the adjacent
striatum. The frequency of apoptotic cells was very low in all
mice, with no significant difference observed between the two
groups (data not shown). There was no morphological evidence
of other brain damage or degeneration in Tam-Idh1-KI mice
(Figures S1D and S1E).Figure 1. Idh1R132H Expression in the SVZ and Its Effects on Weight, B
(A) The construct used to generate Tam-Idh1-KI mice is shown. After homologo
deletion of (1) a mini-gene containing Idh1wild-type exons 3–9; (2) termination co
from the native promoter. The following features are shown: loxP and Frt sites; 50
signal; neomycin resistance cassette (NeoR); location of the R132H mutation.
(B) The panels show expression of the YFP reporter in the anterior SVZ (left) and
induction. cc, corpus callosum; str, striatum; sep, septum; LV, lateral ventricle.
(C) Tamoxifen dosage schedule is shown. Asterisks indicate time points of brain
(D) Sequencing chromatogram shows genomic DNA or cDNA of a region arou
indicated. Arrows indicate nucleotides altered in Idh1R132H (c. 395–396 CGA > C
(E) Kaplan-Meier plots show the survival of Tam-Idh1-KI (n = 28) and control (n =
(F) Body weights of paired Tam-Idh1-KI and control mice are shown.
(G) Open field test measures of locomotion (no. of squares crossed) and activity
(H) Whole-brain dissections show frontal and parietal lobe morphology in Tam-Id
(I) MRI illustrates LV volumes (arrows) in Tam-Idh1-KI mice and controls. Sec
Tam-Idh1-KI mice and three controls are shown in the chart.
All data are presented as mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.005). See alsIdh1R132H Increases the Numbers of Stem and
Progenitor Cells in the SVZ
Wenext examinedTam-Idh1-KImice using immunofluorescence
(IF) for cellular phenotypes related to tumorigenesis, including
proliferation, differentiation, and migration. Owing to the abnor-
malities found in H&E sections, we focused on the SVZ. IF-based
quantitation confirmed that, compared with controls, Tam-Idh1-
KImice showeda larger SVZvolume (1.15-fold, p = 0.041), similar
cell density (p = 0.20), and a larger number of cells (p = 0.047).
To better evaluate the proliferative dynamics of the SVZ and to
obtain information regarding which cell populations (Figure S2A)
were expanded in Tam-Idh1-KI animals, mutant and control
mice were injected with BrdU in three consecutive daily doses,
followed 13 days later by a pulse of EdU 2 hr before sacrifice (Fig-
ure 3A). The BrdU label-retaining cells in the SVZ correspond to
relatively quiescent NSCs, but not their progeny, TAPs, which
divide frequently. The EdU label is found in cells cycling at the
time of injection. We carried out double IF of EdU and GFAP (Fig-
ures 3B and 3C) and triple IF of Ki67, BrdU, and GFAP (Figures
3D and 3E), and quantified SVZ cells with confocal microscopy.
We analyzed the number of cells per unit volume to control for
the increased size of the mutant SVZ. The proportions, and
hence total numbers, of EdU+ (rapidly proliferating or re-entering
cell cycle), GFAP+ (mainly NSCs and niche astrocytes), and
EdU+GFAP+ cells (proliferating NSC or niche astrocytes) were
increased in Tam-Idh1-KIs (Figure 3C). The proportions and
numbers of Ki67+ (cycling) and BrdU+ (quiescent or slowly
cycling) cells also increased in the mutant SVZ (Figure 3E).
Both Ki67+GFAP+ and BrdU+GFAP+ proportions were higher in
the mutant SVZ, suggesting that the number of label-retaining,
as well as actively dividing, astrocytic stem cells was increased.
This was confirmed by the significantly higher proportion and
number of BrdU+Ki67+GFAP+ cells in the mutants, suggesting
that more NSCs became activated and re-entered the cell cycle.
A more detailed analysis of the Ki67, BrdU, and GFAP triple IF
found an overall highly significant difference in the proportions
of cell types between Tam-Idh1-KIs and controls (c25 = 43,
p < 0.001). The increased cell populations included quiescent
and activated NSCs and, to a smaller degree, TAPs (Figure S2B).
We also assessed the oligodendrocyte progenitor marker
Pdgfra and Olig2, a marker of the entire oligodendroglial lineage
that is universally expressed in diffuse gliomas (Ligon et al.,ehavior, and Lateral Ventricle Size in Adult Mice
us recombination into the endogenous Idh1 locus, expression of Cre causes
don and SV40 polyA signal; and (3) NeoR cassette. Idh1R132H is then expressed
and 30 homology arms (HAs); wild-type mini-gene (exons 3–9) and SV40 polyA
mid-SVZ (right) of Nes-CreER(T2);R26R-EYFP mice 29 weeks after tamoxifen
collections.
nd Idh1 codon 132 from forebrain or SVZ of control or Tam-Idh1-KI mice as
AT).
32) mice from 18 litters.
(no. of rears) are shown.
h1-KI and control animals.
tions were taken at comparable locations. Estimated LV volumes of three
o Figure S1.
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Figure 2. Histology and Proliferation of SVZ
in Tam-Idh1-KI and Control Mice
(A) H&E staining of sagittal sections from control
and Tam-Idh1-KI mice is shown. The anterior
commissure is indicated by arrows.
(B) Ki67 immunohistochemistry is shown in sagittal
sections at comparable medio-lateral positions
from Tam-Idh1-KI and control mice. Ki67+ cell
clusters ectopic to the SVZ are arrowed. Areas in
the insets are magnified.2004; Suzuki et al., 2014) (Figures 3F and 3G). The proportions and
numbers of Pdgfra+Olig2+ and total Olig2+ cells were both
increased in Tam-Idh1-KI mice compared with controls. A similar
increase was found for the neuroblast marker Dcx (details not
shown).
We assessed Ki67, GFAP and Olig2 expression in younger
mice that had received tamoxifen at 5–6 weeks of age and582 Cancer Cell 30, 578–594, October 10, 2016were analyzed 3–8 weeks later.
Compared with controls, the younger
Tam-Idh1-KI mice showed similar GFAP
and Olig2 changes to those observed
previously in older animals, although the
Ki67 increase was smaller (details not
shown). The younger mice also had an
expanded SVZ, a diffuse RMS and
ectopic cells. These data suggest that
the Tam-Idh1-KI phenotype can develop
quite rapidly but may also progress over
time.
In summary, Idh1R132H increased the
proportions and numbers of quiescent
NSCs and their proliferative progeny
(activated stem cells, progenitor cells,
and partly differentiated cells) in both
young and older mice, thereby enlarging
the SVZ (Figure S2C). A parsimonious
explanation for these findings is a primary
effect of the mutation on quiescent
NSCs, although additional effects in their
progeny cannot be excluded.
Idh1R132H Induces Infiltration into
the Parenchyma
The confines of the SVZ and neuroblast
migration in the healthy brain are tightly
controlled, with the high density of cells
making it easy to distinguish these re-
gions from adjacent tissue. Migratory
SVZ cells mostly move to the olfactory
bulb (OB), with few emigrating from the
SVZ or RMS to the adjacent parenchyma
(Lois and Alvarez-Buylla, 1994). The Tam-
Idh1-KI SVZ was enlarged, and its border
was not clearly delineated (Figures 2
and 3). As expected, in controls, the great
majority of BdU+, Ki67+, or EdU+ cells
were restricted to the SVZ (Figures 4A,S3A, and S3B). In contrast, Tam-Idh1-KI mice contained large
numbers of actively mitotic Ki67+ or EdU+ cells, as well as
label-retaining BrdU+ cells, adjacent to and contiguous with
the SVZ, in locations equivalent to those of the striatum and
corpus callosum in wild-type mice (Figures 4A and S3). Similarly,
Tam-Idh1-KI brains displayed increased numbers of GFAP+ cells
in both the SVZ and surrounding parenchyma, whereas GFAP
Figure 3. The Effect of Idh1R132H on Label-Retain-
ing Cells, Proliferating Cells, and Oligodendro-
cytes in the SVZ
(A) The time course of BrdU and EdU injections is shown.
(B) For the analysis of rapidly cycling cells, EdU and GFAP
expression in the SVZ was determined. Representative
images showing EdU and GFAP expression were derived
from coronal sections from four Tam-Idh1-KI and four
control mice. The left-hand image at the bottom of each
panel is a magnified orthogonal 3D view of the GFAP+
EdU cell marked by an arrowhead; and the adjacent
right-hand image is the equivalent view of theGFAP+EdU+
cell marked by an arrow. Dashed lines outline the SVZ.
(C) Z stack quantifications of each cellular population from
(B) are shown in the chart as ‘‘density’’, which is a mea-
sure of the proportion of each cell type. Total EdU+ and
GFAP+ cells are shown, followed by a breakdown of these
into the component categories and an EdUGFAP- group.
(D) For analysis of label-retaining cells, BrdU, Ki67, and
GFAP expression was assessed. The left-hand image at
the bottom of each panel is a magnified orthogonal 3D
view of the GFAP+BrdU+ cell marked by a white arrow;
the adjacent middle image is the equivalent view of
the GFAP+Ki67+ cell marked by a white arrowhead;
and the adjacent right-hand image is the equivalent view
of the GFAP+BrdU+Ki67+ cell marked by a yellow arrow.
Other annotation is as per (B).
(E) The chart shows quantification of each directly coun-
ted, marker-positive cell population from (D). Note that
BrdU+ cells may have any Ki67 and GFAP status and
BrdU+Ki67+ cells include both GFAP+ and GFAP cells.
(F) Olig2+ (pan-oligodendrocyte) and Pdgfra+ (pro-
genitors) expression are shown. The image at the extreme
right of each panel is a magnified orthogonal 3D view of
the Olig2+Pdgfra+ cell indicated by a white arrow. Other
annotation is as per (B).
(G) The chart shows quantification of cell populations
from (F). Note that Olig2+ includes cells with any Pdgfra
status.
All data are presented asmean ± SD (*p < 0.05, **p < 0.01,
***p < 0.005). See also Figure S2.
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Figure 4. The Effect of Idh1R132H on Tissues Surrounding the Dorsolateral Corner of the SVZ
(A) Ki67, BrdU, and GFAP expression are shown in coronal sections of Tam-Idh1-KI and control brains. Dashed lines outline the LV, around which the SVZ usually
forms a ribbon of cells. The data are quantitated in the bar chart below.
(B) Cells expressing oligodendocyte (Olig2+) and neuroblast (Dcx+) markers are shown. The data are quantitated in the bar chart below.
All data are presented as mean ± SD (*p < 0.05, **p < 0.01, ***p < 0.005). See also Figure S3.
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expression was almost exclusive to the SVZ and corpus
callosum in controls (Figures 4A, S3A, and S3B). BrdU+ label-re-
taining GFAP+ astrocytes that were actively proliferating (Ki67+)
were present in the striatum of Tam-Idh1-KI brains but absent
in control mice (Figures 4A, S3A, and S3B). These data were
consistent with Tam-Idh1-KI causing the SVZ to expand and/or
SVZ cells to migrate out of their local boundaries and proliferate
in ectopic locations adjacent to the neurogenic niche.
To further understand these regions of hyperproliferation, we
assessed expression of Dcx, a marker of immature migratory
SVZ neuroblasts, and Olig2. Compared with controls, Tam-
Idh1-KI mice contained significantly more Dcx+ cells and
Olig2+ cells in the striatum and corpus callosum (Figures 4B
and S3C–S3E). Higher magnification showed that many of the
ectopic Dcx+ cells had bipolar morphology with leading pro-
cesses, suggestive of migration. Transformed cells and SVZ
cells in pathological conditions can express multiple lineage
markers (Jablonska et al., 2010), but the proportion of cells
that were Dcx+/Olig2+ was small and did not change in the
Tam-Idh1-KI mice (Figure 4B).
Migration in the RMS is highly regulated, similar to the SVZ. All
seven Tam-Idh1-KI mice analyzed (five old and two young) had a
more diffuse RMS (Figure 5A), with dispersed Dcx+ cells
migrating in various orientations. In addition, in contrast to
controls, all Tam-Idh1-KI mice examined exhibited Dcx+ cells,
sometimes in massive numbers, in the ventral cerebral cortex,
dorsal to the RMS, suggesting emigration from it (Figure 5A).
This was consistent with their ectopic location near the dorsolat-
eral SVZ (Figure 4). Additional abnormalities consistent with
increased stem-like cells and aberrant migration were also found
in the OBs of Tam-Idh1-KI animals (Figures 5, S4A, and S4B).
Compared with controls, Tam-Idh1-KI animals contained
significantly more BrdU+, Dcx+BrdU+, and NeuN+BrdU+ cells in
the granule layer (data not shown) and the OB as a whole (Fig-
ure 5A), indicating that neurogenesis was increased in the
Tam-Idh1-KI mice, probably due to the increased numbers of
stem and/or proliferating SVZ cells. The proportion of BrdU+
cells that expressed differentiation/lineage markers (NeuN,
Dcx, GFAP, and Olig2) was similar in controls and mutants, sug-
gesting that the cells retainedmuch of their normal differentiation
capacity (data not shown).
Interestingly we also found that the OBs of Tam-Idh1-KI mice
contained a larger number of BrdU+ cells that were negative for
neuronal markers (Figure 5A), suggesting that glial cells may
have been generated in the OB. To study this possibility, we
quantified GFAP+ astrocytes and Olig2+ oligodendrocytes that
retained BrdU. GFAP+BrdU+ cell numbers were significantly
increased in the OBs of Tam-Idh1-KI mice, and the number ofFigure 5. The Effect of Idh1R132H on Neurogenesis and Astrocyte Gene
(A) BrdU, Dcx, and NeuN expressing cells (neurogenesis) are shown in represen
image at the bottom of each panel is a magnified orthogonal 3D view of the Brd
equivalent view of the BrdU+Dcx+NeuN cell marked by awhite arrowhead; and th
marked by a yellow arrow. RMS, rostral migratory stream; GCL, granule cell layer;
cell counts are quantitated in the bar chart.
(B) BrdU, GFAP, and Olig2 (astrocyte genesis) data are shown from the same m
orthogonal 3D view of the BrdU+GFAP+ cell marked by a white arrow; and the a
marked by a white arrowhead. Other annotations are as per (A).
(C) A schematic of the multi-layered cellular architecture of a mouse OB is show
All data are presented as mean ± SD (*p < 0.05, ***p < 0.005). See also Figure S
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(Figure 5B).
To confirm that the SVZ was the source of the mislocalized
cells, we traced the Nes-Cre-expressing cell lineage using
control and Tam-Idh1-KI mice that also carried the Rosa26-
YFP reporter allele (Srinivas et al., 2001). As expected in the
control crosses, YFP+ cells were restricted to regions of endog-
enous nestin expression: the SVZ and RMS (Figures S4C–S4E).
In the crossed Tam-Idh1-KI mice, many YFP+ cells were found
in an expanded SVZ and RMS, and also in ectopic locations
continuous with the neurogenic niche (Figures S4C–S4E).
These included the corpus callosum, striatum next to the SVZ
as well as regions adjacent to the RMS. This lineage experi-
ment supported the model that the SVZ and RMS expansion
and infiltration into adjacent brain regions was initiated from
nestin-positive cells, which were originally most likely present
in the SVZ.
Disruption of the glial tubes composed of B1 astrocytes and
B2 niche astrocytes is often characteristically associated with
abnormal migration of neuroblasts (Comte et al., 2011). To
address this, we examined the RMSwith GFAP IF and compared
it with the distribution of YFP+ cells. Although the YFP+ cells were
expanded in the RMS of mutant animals, we did not find that the
glial tubes were altered in morphology in mutant mice compared
with controls (data not shown). This suggests that the
emigration/infiltration of the neuroblast progenitors, as well
as the glial progenitors, into the regions adjacent to RMS and
SVZ is probably cell autonomous.
These results suggest that expression of Idh1R132H in adult
mouse stem/progenitor cells robustly induced expansion of the
SVZ and RMS and infiltration into adjacent regions, similar to
observations of glioma cell invasion. The SGZ showed similar
features (Figure S4F). While cell numbers were increased in the
Idh1-mutant animals, the cells appeared to retain their capacity
for differentiation.
Tam-Idh1-KI Mice Develop Proliferative Subventricular
Nodules
In all Tam-Idh1-KI mice studied, apart from three killed only 2,
3, and 6 weeks after tamoxifen administration, we found small
(up to 1 mm diameter) nodules originating from the SVZ and
protruding into the LVs (Figure 6A). The lesions, which were ab-
sent from control animals, could be found at any location in the
walls of the LVs. The nodules expressed proliferation markers,
such as Ki67 (Figures 6B and 6C), and retained BrdU label (Fig-
ure 6C), suggesting that they exhibited a variety of proliferative
behaviors. As shown in Figure 6C, several cells present in the
nodules were Ki67+BrdU+, indicative of label-retaining cellssis in the Olfactory Bulb
tative images from Tam-Idh1-KI (n = 4) and control (n = 4) OBs. The left-hand
U+DcxNeuN- cell marked by a white arrow; the adjacent middle image is the
e adjacent right-hand image is the equivalent view of the BrdU+DcxNeuN+ cell
IPL, internal plexiform layer; ML, mitral layer; EPL, external plexiform layer. The
ice as in (A). The left-hand image at the bottom of each panel is a magnified
djacent right-hand image is the equivalent view of the BrdU+DcxNeuN+ cell
n. GL, glomerular layer. Other annotations are as per (A).
4.
(legend on next page)
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that had re-entered the cell cycle. Many nodule cells also
expressed the astrocytic and NSC marker GFAP and in some
lesions, a few cells expressed the neuroblast marker Dcx
(Figures 6C and 6D). Using a reporter mouse cross, we found
that the nodules expressed YFP, consistent with origins from
nestin-expressing stem or TAP SVZ cells (Figure 6E). Micro-
scopic inspection of the nodules revealed clustered cells,
with hyperchromatic nuclei and scant cytoplasm that were
clearly distinct from the overlying ependymal lining (Figure 6A).
Some of the nodules were not continuously covered by S100b+
ependymal cells, suggesting that subventricular lesions had
broken through the ventricular lining (Figure 6F). The ependy-
mal layer, as assessed by S100b expression, otherwise
appeared normal (Figure 6G).
The Idh1fl(R132H)/+ Allele Is Leaky and Causes a Brain
Phenotype in a Minority of Juvenile or Aged Mice
We had noted that 10% (9/94) of Idh1fl(R132H)/+ mice without the
Nes-Cre transgene and 8% (5/62) of non-induced Nes-CreER(T2);
Idh1fl(R132H)/+ animals developed rounded and enlarged skulls
at 3–6 weeks of age. This phenotype, reminiscent of human
hydrocephalus prior to fusion of the skull sutures, necessitated
immediate culling. Ventricular nodules, similar to those in Tam-
Idh1-KI mice, were found in these animals (Figure 7A.) We
aged some surviving Idh1fl(R132H)/+ animals (after tamoxifen in-
jections) for 1–2 years. Although none showed symptoms or
signs of disease while alive, upon postmortem investigation,
8/34 animals (24%) had ventricular enlargement. Of those eight
mice, histological examination showed one to have a clearly
enlarged, diffuse SVZ (Figure 7B) and another to have a single
subventricular nodule (Figure 7C). The brains of these mice
accumulated 2HG, but there was no evidence of other brain
damage (data not shown). We also aged three Nes-CreER(T2);
Idh1fl(R132H)/+ animals that had not received tamoxifen, and all
showed a similar phenotype to the eight Idh1fl(R132H)/+ mice
without Nes-Cre. Further investigation strongly suggested that
the phenotype resulted from expression of an Idh1 mRNA that
lacked exons 1 and 2 and was derived from the mouse construct
(Figures 1A, 7D, and 7E). We found that the short RNA was a
physiological isoform, as it was also produced by the wild-type
Idh1 allele. Idh1 exons 1 and 2 have no homology to any
other protein, are not conserved, and contain no functional do-
mains of predicted importance. A search of the genomic
DNA sequence revealed a potential translation initiation site
in intron 2 that would leave the enzyme active site intact
(Figure 7F). We conclude that in a minority of mice, a leaky
Idh1R132H allele can produce a forme fruste of the full
Tam-Idh1-KI phenotype.Figure 6. Nodule Formation in the SVZ
(A) Typical morphology of a nodule protruding into the lateral ventricle (LV) is sho
(B) Ki67 expression was assessed in a nodule and at other sites along the LV wa
(C) Nodule proliferation was assessed by immunofluorescence for Ki67 and Brd
lineage marker GFAP is also shown.
(D) Immature neuroblast differentiation in nodules was assessed using Dcx.
(E) The origin of nodules from nestin-expressing cells was assessed using the YFP
callosum are also marked.
(F) Ependymal cell-specific S100b expression indicates the extent of the continui
nodules from ependymal cells. Three nodules are shown (left), magnified in the i
(G) A high-power view compares the ependymal cell layer in Tam-Idh1-KI and co
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Tam-Idh1-KI Phenotype
Attempts to culture primary Idh1-mutant neurospheres from the
SVZ of Tam-Idh1-KI mice were unsuccessful. We therefore
stably expressed IDH1R132H both in human neuronal stem/pro-
genitor cells (ReNcell CX) and in primary SVZ cells dissected
from wild-type BL6 mouse pups. In each case, IDH1R132H
increased the size and number of neurospheres cultured from
human NSC/NPCs (Figures 8A and 8B). These data were consis-
tent with increased proliferation and self-renewal capacity of the
mutant NSC/NPCs in vivo.
We also measured the capability of ReNcell CX expressing
IDH1R132H to migrate in vitro, in unstimulated or chemoattractant
(20 mg/mL FGF or 5% serum) conditions. IDH1-mutant cells
were significantly more motile than control cells (1.8-fold in
all conditions; ANOVA, p < 0.0001; details not shown). These
data were in accordance with the infiltrative behavior of
Idh1-mutant NSC/NPCs in vivo.
Using capillary electrophoresis time-of-flight mass spectrom-
etry (CE-TOFMS), we performed a comprehensive analysis of
metabolites in Tam-Idh1-KI and control mice. In Tam-Idh1-KI
samples, we detected 2-fold increase in total 2HG and
30% decreased aKG compared with controls (Figure 8C).
The leaky mice showed similar changes but at lower levels (de-
tails not shown). The changes in adults appeared less substantial
than those found in the brains ofNes-Cre; Idh1fl(R132H)/+ embryos
using IC-MS (Figure S5A). No significant differences were de-
tected in any other metabolite, including glycolytic, TCA cycle,
and pentose phosphate pathway intermediates.
We found no clear evidence that collagen-PHDs, ROS, HIF-
PHDs, or JHDMs were altered in the Tam-Idh1-KI mice (Figures
S5B–S5F, Table S1). In contrast, in the forebrains of Tam-Idh1-
KIs and controls, global abundance analysis by high-perfor-
mance liquid chromatography (HPLC) showed significantly
decreased 5hmC and raised 5mC (Figure 8D). Although the latter
was formally non-significant, low-coverage single-base resolu-
tion analysis using methyl-seq (WGoxBS) showed significantly
increased 5mC in the SVZ of Tam-Idh1-KI animals (Figures 8E
and S6A–S6D). The greatest absolute increase in 5mC was
outside CpG islands, although the relative increase was similar
across all genomic regions (Figure 8E). In summary, Idh1R132H
mutation led to a global decrease of 5hmC and increase of
5mC, consistent with tumor-promoting effects.
mRNA Expression Profiling in Tam-Idh1-KI Mice
Identifies Pathways of Tumorigenesis
To uncover molecular pathways that might underlie the pheno-
type of the Tam-Idh1-KI mice, we performed transcriptionalwn in an H&E-stained section from a Tam-Idh1-KI animal.
ll.
U. Two nodules are shown (left), magnified in the inset (right). The astrocyte
reporter. The dashed lines outline the nodules. YFP+ cells infiltrating the corpus
ty of the ependymal cell layer overlying the nodules and potential origins of the
nsets (right).
ntrol mice.
Figure 7. Leaky Phenotype in a Minority of
Idh1fl(R132H)/+ Mice without Nes-Cre
(A) A coronal full-brain section from a symptomatic
Idh1fl(R132H)/+ mouse 6 weeks old is shown.
A nodule is outlined and magnified.
(B) Detailed SVZ morphology of an asymptomatic
4 month old Idh1fl(R132H)/+mouse is shown (sagittal
section).
(C) A nodule is present in an asymptomatic
13 month old mouse (sagittal section).
(D) The Idh1 transcript lacking exons 1 and 2
was amplified from cDNA by endpoint RT-PCR
(amplicon size 562 bp).
(E) DNA sequencing chromatogram shows
genomic DNA or cDNA specifically derived from the
short transcript in the Idh1 region around codon
132 (samples from mouse forebrain). Arrows indi-
cate nucleotides altered in Tam-Idh1-KI and
Idh1fl(R132H)/+; dashed lines provide an indication of
the relative dosages of wild-type and mutant short
transcript in each case.
(F) Schematic of short in-frame Idh1 transcript
lacking exons 1 and 2 shows the putative trans-
lational origin in intron 2.
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profiling of SVZ cells from mutant and control animals. Gene set
enrichment analysis (GSEA) revealed several pathways and pro-
cesses of note that were more active in Tam-Idh1-KIs than con-
trols at a false discovery rate <0.05 (Figures 8F and S6E, Table
S1). Notably, these included brain-tumor-associated processes
matching the mouse phenotype such as stemness, cell cycle,
maintenance of telomeres, and DNA replication. This analysis
also showed significant increases in gene sets specific to human
glioblastomas, including the proneural sub-type, which is char-
acterized by mutation of IDH1 (Verhaak et al., 2010) (Figures
8F and S6E). Interestingly, both Wnt and c-Myc target genes
were also overexpressed in Tam-Idh1-KIs, suggesting potential
molecular mechanisms for the gliomagenesis phenotype.
DISCUSSION
We have shown that conditional, inducible expression of the
Idh1R132H mutation in the adult mouse SVZ stem cell niche
causes cellular and molecular features associated with brain
tumorigenesis. We found three critical phenotypes in the SVZ
niche: (1) increased numbers of label-retaining stem cells as
well as acutely proliferating cells in and around the SVZ and
RMS; (2) significant infiltration of neuronal and glial progenitors
from the SVZ and RMS into surrounding regions; and (3) subven-
tricular nodules containing proliferating stem/progenitor cells
that protruded into the LV from the SVZ. The mutant animals
developed dilation of the LVs, with accompanying distortion of
the cerebrum and clinically apparent hydrocephalus. However,
the brains showed little, if any, evidence of neural damage or
degeneration and appeared largely normal histologically in re-
gions away from the niche.
The phenotypic dissimilarities between our Tam-Idh1-KI and
other Idh1/2 models probably resulted from our targeting of
Idh1R132H to the neurogenic niches of the adult brain. Nestin-
Cre causes recombination early in the SVZ lineage and can affect
large numbers of NSCs (Lagace et al., 2007). However, nestin is
also expressed in other SVZ cells, including TAPs and niche as-
trocytes (Doetsch et al., 1997), and all of these may have been
influenced by the Idh1mutation. Given the relatively large expan-
sion of quiescent NSCs and the overexpression of stem cellFigure 8. Assessment of Functional Mechanisms Underlying the Tam-
(A) The experiments determined the effects of IDH1R132H expression in ReNcell
mutant IDH1 in cells transduced by IDH1R132H or GFP lentiviral vectors compared
(c) Representative bright-field images are shown for ReNcell CX cells (IDH1R132
rospheres at low density. The chart shows quantification of neurospheres grown a
using high and two using low density cultures, giving consistent results. Results
(B) Tertiary neurospheres were derived from primary SVZ cells transduced with le
representative transduction efficiency. (b) After 4 days in culture, the size and num
and self-renewal capacity. The chart shows a representative experiment of three
Results are presented as means ± SEM (**p < 0.01, ***p < 0.005). (c) Representativ
density are shown.
(C) Mass spectrometric assessment of the effect of Idh1R132H on 2HG and aKG l
controls (n = 3) aged 4–9 months were assayed for total 2HG (D and L isomers).
chart, presented as means ± SD. *p < 0.05, **p < 0.01, from ANOVA.
(D) Total 5hmC and 5mC levels of forebrain were assessed using denaturing HP
(E) 5mC genome sequencing was performed on SVZ DNAs. (a) Levels of cytosine
age and sex are shown, ***p = 0.0163, from Kolmogorov-Smirnov test. (b, c) Abso
flanking regions. (d) Hierarchical cluster analysis of top 2,000 differentially methy
(F) mRNA expression GSEA analysis is shown for selected gene sets enriched in
See also Figures S5 and S6, Table S1.markers in Tam-Idh1-KI mice, our data suggest that an early
stem cell was targeted by Nes-Cre. The leakiness of the
Idh1fl(R132H)/+ allele may also have contributed to the Tam-
Idh1-KI phenotype. Evidence strongly suggests that the pheno-
type caused by the leaky allele also originates in the SVZ. First,
although the leaky allele causes 2HG accumulation in all tissues
examined, no phenotype outside the brain was detected. Sec-
ond, the phenotypes of Tam-Idh1-KI and leaky mice are very
similar, notwithstanding much reduced penetrance and severity
in the latter. Third, nestin expression is not induced by 2HG
outside the SVZ and SGZ in the leaky mice; thus, while Tam-
Idh1-KI mice are produced from an allele that is already leaky,
when tamoxifen is given, full R132H knockin occurs in the SVZ
and SGZ. Although leaky R132H expression in cells outside
the SVZ could in theory explain the more numerous and mis-
placed cells in the striatum, corpus callosum, RMS, and OB in
Idh1 mutants, lineage tracing in Tam-Idh1-KIs showed that the
cells undergoing recombination in the SVZ after tamoxifen
administration could account for the great majority of these cells.
Tsc1-cKO (Nes-CreER(T2); Tsc1loxP/loxP) mice also develop hy-
drocephalus, periventricular nodules, and tumor-like structures
near the inter-ventricular foramen (Feliciano et al., 2012; Zhou
et al., 2011). The Tsc1-KO lesions are Dcx+ and were mostly
non-proliferative, in contrast to our mice. The causes of
ventricular dilation and hydrocephalus were not identified in
the Tsc1-KOs, although cryptic nodules obstructing CSF flow
or disrupting the ependymal lining are possible causes. Mice
overexpressing Tlx, a key regulator of NSC expansion, also
develop periventricular nodules, accompanied by SVZ and
RMS changes similar to the Tam-Idh1-KIs but without the gross
phenotype of our animals (Liu et al., 2010). We found increased
expression of Tlx targets in the Tam-Idh1-KI mice (Table S1).
Several theories as to how the IDH1R132H mutation drives
cancer were not supported by our work, including hypoxia
pathway activation, increased angiogenesis, altered collagen,
histone methylation, and ROS. We caution that the SVZ tissue
analyzed may have contained some non-induced cells, diluting
out effects. We did find that Idh1R132H animals had raised 2HG
and decreased aKG, accompanied by reduced 5hmC and
increased global 5mC in DNA. IDH2 and TET2 mutations areIdh1-KI Phenotype
CX neuronal progenitor cells. (a) western blot shows expression of total and
with untransduced cells. (b) GFP expression indicates transduction efficiency.
H-transduced or untransduced controls) grown as primary or secondary neu-
t a low density. Data are representative of three independent experiments, one
are presented as means ± SEM (***p < 0.005).
ntiviruses expressing IDH1 wild-type (WT) or R132H. (a) GFP expression shows
ber of WT and IDH1R132H neurospheres were measured to assess proliferation
independent experiments, two using high and one using low density cultures.
e images of IDH1-wild-type and IDH1R132H neurosphere cultures grown at high
evels was performed. Brain tissue extracts from Tam-Idh1-KI mice (n = 4) and
Data are shown as dot plots and summarized as relative expression in the bar
LC. Data are presented as means ± SD.
methylation at CpG dinucleotides in Tam-Idh1-KI (T) and controls (C) paired by
lute (b) and relative (c) differences in CpG methylation within CpG islands and
lated CpGs to assess whether mutants and controls clustered separately.
Tam-Idh1-KI brains.
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mutually exclusive in AML (Figueroa et al., 2010; Gaidzik et al.,
2012), and it has been reported that expression of mutant IDH
or administration of 2HG can inhibit TET2 in vitro and in vivo, re-
sulting in decreased production of 5hmC (Figueroa et al., 2010;
Sasaki et al., 2012a; Xu et al., 2011) and reduced DNA demethy-
lation (Pastor et al., 2013). TET activity might also be limited by
reduced aKG availability. The increased DNA methylation in
Tam-Idh1-KI brains is correspondingly present in human IDH1-
mutant tumors (Guilhamon et al., 2013; Lu et al., 2012; TCGA,
2015; Sturm et al., 2012), but the pattern of changes appears
to differ, the former being global and relatively uniform and the
latter, targeting CpG islands (CIMP). It is of note that CIMP has
often been measured using microarrays that focus on CpG
islands, with much less coverage of other CpGs. Therefore,
some cases scored as CIMP+ may actually possess a tendency
to genome-wide methylation. Furthermore, a global methylator
phenotype could cause CIMP by the selection of epimutations
at CpG islands during tumorigenesis.
mRNA expression profiling showed Tam-Idh1-KI mice to have
increased c-Myc and Wnt pathway activity, higher numbers of
cycling cells, upregulated telomere maintenance, and more cells
with a stem-like phenotype. Culture of human neuronal stem/
progenitor cells supported the mouse data by showing
increased self-renewal and proliferation in cells expressing
IDH1R132H. All of these functional processes are strongly mech-
anistically associated with tumorigenesis. Tam-Idh1-KI mice
also expressed high levels of genes associated with IDH1-
mutant human brain tumors.
Together, our findings show that expression of mutant Idh1 re-
capitulates cellular and molecular features of gliomagenesis,
including stem cell features, increased proliferation, infiltration
into adjacent structures, and tumor-like nodules originating
from nestin-expressing cells. Our data suggest that the underly-
ing cellular defect in the Tam-Idh1-KI mice is an increased and
poorly controlled number of dividing stem/progenitor cells that
retain much of their differentiation capacity, thus potentially
representing the earliest phase of IDH-driven gliomagenesis.
Our mice provide insights into human IDH1-driven brain tumors
and a model system for assessing therapies.EXPERIMENTAL PROCEDURES
Procedures are detailed in the Supplemental Experimental Procedures and
summarized here. All mouse experiments were performed in accordance
with institutional and national guidelines and regulations under UK Home
Office Project Licence PPL 3003311. For the Tam-Idh1-KI model, mice
received intraperitoneal tamoxifen injections to induce Nes-Cre-mediated
recombination, causing the R132H protein to be expressed. For analysis of
mRNA and proteins, snap-frozen tissue was obtained for analysis after
sectioning brains and carefully removing the SVZ or other region under a dis-
secting microscope. For fixed tissue analysis, mice were transcardially
perfused with normal saline and 4% paraformaldehyde (PFA). Brains were
removed, post-fixed in 4% PFA, cryoprotected in 30% sucrose, and frozen.
Sections were cut on a sliding microtome, and kept at 20C. Sections
were stained using standard free-floating IHC. Numbers of immune-positive
cells were counted in confocal microscopy z stacks. All quantifications were
done by an observer blinded to mouse genotypes.
Molecular assays were performed using standard protocols for (1) 5mC and
5hmC (HPLC and next-generation sequencing), (2) TCA cycle and other me-
tabolites (mass spectrometry); and (3) mRNA expression profiling (Illumina
Mouse WG6-v2 microarrays). Western blotting was performed to assess the592 Cancer Cell 30, 578–594, October 10, 2016expression of selected proteins (hypoxia, ROS, histone modification,
collagen), supplemented by qRT-PCR for mRA where appropriate.
For all phenotypic assessments, including molecular studies, tamoxifen-
treated, Tam-Idh1-KI animals were compared with paired, tamoxifen-treated,
littermate controls (Idh1+/+, with or without Nes-Cre transgene). Cell lineage
and proliferation analysis was performed using immunofluorescence for
DNA labeling agents (BrdU, EdU), proliferation marker (Ki67), and markers of
differentiation (GFAP, Olig2, NeuN, Dcx, S100b, Pdgfra). Assessment of tissue
morphology was performed using H&E-stained sections, supplemented by
IHC for selected markers.
Assays to assess the effect of IDH1R132H were performed by expressing the
mutant protein in ReNcell CX from human fetal cerebral cortex or neural stem/
progenitor cells from P4 wild-type mice. Assays performed on these cells
included primary and second neurosphere formation and transwell motility.
All data are presented as means ± SDs, with nominal p values from unpaired
t tests, unless specified otherwise in the figure legend.
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